The Bayer Roundup settlement, finalized at $7.25 billion, divides claimants into distinct tiers based on the severity of their cancer diagnosis and the strength of their claim. Tier 1 claimants—typically those with multiple Roundup-related cancers or diagnosed before age 21—receive the highest payouts, ranging from $100,000 to over $250,000 per case. Tier 2 claimants with a single, well-documented non-Hodgkin’s lymphoma diagnosis receive between $25,000 and $100,000, while Tier 3 claimants with other cancer types or weaker evidentiary records may receive between $5,000 and $25,000.
A person diagnosed with non-Hodgkin’s lymphoma at age 35 after documented residential exposure to Roundup would typically fall into Tier 2, potentially receiving a settlement between $50,000 and $80,000 depending on medical records and exposure evidence. This multi-tiered approach means that not all Roundup cancer victims receive the same compensation. The settlement administrators review each claim individually, examining medical records, pathology reports, employment history, and documented Roundup exposure. Some claimants may qualify for higher tiers based on aggravating factors, while others see their payouts reduced or their claims denied if the evidence doesn’t sufficiently establish causation between Roundup exposure and their cancer diagnosis.
Table of Contents
- How Does Bayer’s Settlement Divide Roundup Cancer Cases Into Tiers?
- What Medical Evidence Is Required to Qualify for Each Tier?
- What Role Does Exposure History Play in Settlement Tier Placement?
- How Long Does the Claims Review Process Take, and When Can You Expect Payment?
- What Happens if Your Claim Is Placed in a Lower Tier Than You Expected?
- What Qualifies as Proof of Roundup Exposure?
- Looking Ahead—Other Roundup Claims and Future Litigation
- Conclusion
How Does Bayer’s Settlement Divide Roundup Cancer Cases Into Tiers?
The settlement structure reflects the legal principle that claimants with stronger cases and more serious health impacts should receive higher compensation. Bayer agreed to a tiered system to avoid prolonged individual trials while still acknowledging that not every claim carries equal weight. The tier determination process begins when a claimant submits their initial claim packet, which includes medical records, pathology reports confirming cancer type, residency or employment records showing Roundup exposure, and any expert medical testimony linking the exposure to the diagnosis. Tier 1 encompasses the most severe or sympathetic cases.
Claimants under age 21 at diagnosis, those with multiple cancers potentially caused by Roundup exposure, or those with non-Hodgkin’s lymphoma complicated by other serious health conditions typically fall here. A 19-year-old diagnosed with NHL after working summers on a landscape crew that regularly applied Roundup would be Tier 1, potentially receiving $150,000 or more. Tier 2 represents the bulk of claimants—adults diagnosed with non-Hodgkin’s lymphoma with clear occupational or residential exposure. Tier 3 captures cases with weaker proof of causation, other cancer types under investigation (such as prostate cancer, which remains more contested in court), or claimants with significant gaps in their exposure history.
What Medical Evidence Is Required to Qualify for Each Tier?
The settlement requires claimants to provide pathology-confirmed cancer diagnoses, not just oncologist opinions or assumed diagnoses. This means obtaining actual tissue reports from the hospital or laboratory where the biopsy was performed. Many claimants assume their doctor’s clinical diagnosis is sufficient, only to discover that the settlement administrators require microscopic confirmation of cancer type.
A claimant who was told verbally that they had “a blood cancer” but never received formal pathology documentation may see their claim downgraded or denied entirely. Additionally, the tiers distinguish between cancer types based on available epidemiological evidence. Non-Hodgkin’s lymphoma has the strongest scientific backing linking it to Roundup exposure (primarily glyphosate), so NHL claimants generally qualify more readily and receive higher payouts. Other cancers—including prostate cancer, lung cancer, and multiple myeloma—remain under investigation or contested, and claimants with these diagnoses typically receive lower tier placements or face denial if the evidence base is deemed insufficient. A person with prostate cancer and Roundup exposure might receive a Tier 3 payout of $10,000 to $20,000, whereas an NHL patient with identical exposure might receive $60,000 to $90,000.
What Role Does Exposure History Play in Settlement Tier Placement?
Documentation of Roundup exposure is often the tipping point between claim approval and denial. The settlement considers occupational exposure (landscapers, farmers, golf course workers, groundskeepers) as well as residential exposure (homeowners who regularly applied Roundup, children living in households where parents used Roundup extensively). The stronger and more specific the exposure timeline, the higher the tier placement. A landscaper with 15 years of direct Roundup application, employment records showing this work, and corroborating coworker statements will be placed higher than a homeowner who used Roundup occasionally on their garden.
Residential exposure claimants face additional scrutiny because homeowner records are often incomplete. A person who used Roundup for 10 years to control weeds in their yard but kept no receipts or photographs will find their claim harder to prove than someone with credit card statements showing annual Roundup purchases, product purchase dates, and documented lawn treatment patterns. The settlement administrators have hired toxicologists and epidemiologists to evaluate whether the stated exposure level would realistically result in the types of absorption and health effects claimed. An applicant who lives in a house near a heavily sprayed agricultural field and has hospital records from the time period of high exposure typically qualifies for a higher tier than someone with vague recollection of occasional Roundup use decades ago.
How Long Does the Claims Review Process Take, and When Can You Expect Payment?
The settlement administration process does not happen overnight. From the time you submit your claim packet until you receive a settlement check typically requires 6 to 18 months, depending on how quickly you provide medical records, how straightforward your case is, and how backlogged the claims administrator’s office becomes. Some claimants waited nearly two years to see payment, particularly if they requested additional reviews or if their initial submission was incomplete.
The payment timeline also depends on your claim’s complexity and whether you accept the settlement amount offered. If the settlement administrator offers you Tier 2 at $60,000 and you request a review believing you qualify for Tier 1, that appeal process can add 4 to 6 months to your timeline. Once you accept the offer and sign the release paperwork, you can typically expect payment within 30 to 60 days. A landscaper who submitted a complete claim with all medical records in January 2023 might have received payment by September 2023, while someone who submitted an incomplete initial claim and had to provide additional documentation could have waited until 2024 for their check.
What Happens if Your Claim Is Placed in a Lower Tier Than You Expected?
If you receive notice that your claim has been placed in Tier 3 when you believe it qualifies for Tier 1 or 2, you have the right to request a review, but the bar for overturning the administrator’s decision is high. The settlement agreement gives the claims administrator broad discretion to categorize cases, and unless you can provide significant new evidence (such as previously undiscovered pathology reports or expert medical testimony), your appeal is unlikely to succeed. Many claimants discover too late that a piece of crucial evidence—a pay stub showing job duties, a hospital discharge summary confirming NHL, a water test showing glyphosate contamination—was missing from their initial submission.
Be aware that the settlement caps total payouts. If far more claimants qualify than the $7.25 billion can accommodate, all remaining claimants may receive reduced payments (a process called “pro-rata reduction”). As of 2024, the settlement faced questions about whether payout reserves would be sufficient, meaning claimants who initially received high-tier offers might see those amounts adjusted downward if the total claims exceed projections. A claimant who was offered $100,000 as a Tier 1 case could theoretically see that amount reduced to $85,000 or $70,000 if the fund is oversubscribed, though the settlement agreement has provisions intended to prevent severe reductions.
What Qualifies as Proof of Roundup Exposure?
Settlement administrators accept multiple forms of exposure evidence, but some carry more weight than others. Employment records (pay stubs, job descriptions, W-2s) showing you worked in roles involving pesticide application are considered strong proof. Photographs of yourself applying Roundup, purchase receipts for Roundup products, and credit card statements showing regular Roundup purchases are valued second-tier evidence. Witness statements from coworkers, family members, or neighbors who observed your Roundup use are tertiary evidence and must be corroborated by other documentation.
Many claimants overestimate how much circumstantial evidence can substitute for direct proof. Saying “I lived on a farm and farmers use Roundup” is not sufficient without connecting yourself specifically to Roundup use or to measurable exposure. A farm worker whose job description explicitly listed “weed control duties” and whose employer used Roundup has a much stronger claim than someone who simply lived on a farm property where Roundup may or may not have been used. Expert testimony about glyphosate residue in water supplies or soil has occasionally been used to establish community-wide exposure, but individual claimants typically need to connect themselves directly to the chemical.
Looking Ahead—Other Roundup Claims and Future Litigation
The $7.25 billion settlement covers eligible claims filed between 2020 and the claim deadline (which varies by state but generally falls several years after the settlement effective date). However, additional Roundup lawsuits continue in various jurisdictions, and people diagnosed with Roundup-related cancers after the settlement claim period may still have options. Some state courts have allowed non-settling claims to proceed, meaning future verdicts could create different payout structures. International litigation also continues, with some countries permitting claims that U.S.
manufacturers managed through Bayer. The settlement also does not preclude future litigation against Bayer’s parent companies or distributors if new evidence emerges about the company’s knowledge of health risks or improper marketing. Claimants who accept the settlement release Bayer from liability but do not waive potential claims against other defendants in the supply chain. As regulations around glyphosate tighten and new scientific evidence accumulates, the legal landscape may shift, potentially creating options for people who did not qualify under this settlement or whose claims were denied.
Conclusion
The Bayer Roundup settlement’s tier structure is designed to allocate $7.25 billion fairly across claimants with varying levels of documented exposure and cancer severity. Tier 1 claimants receive the highest compensation ($100,000-$250,000+), typically those under age 21 at diagnosis or with multiple Roundup-related cancers. Tier 2 claimants with well-documented non-Hodgkin’s lymphoma receive mid-range payouts ($25,000-$100,000), while Tier 3 claimants with weaker evidence or other cancer types receive $5,000-$25,000.
Success in obtaining a higher tier placement depends heavily on complete medical documentation, clear exposure evidence, and timely submission of your claim. If you believe you have a valid Roundup cancer claim, begin by gathering your pathology reports, medical records from the time of diagnosis, employment records showing pesticide exposure, and any receipts or documentation of Roundup use. Contact the official settlement claims administrator (not a third-party legal referral service) to verify your eligibility and understand which tier your case might qualify for. The window for filing claims is limited, and incomplete submissions are a common reason claimants receive lower tier placements than they deserve.